Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cardiovascular outcomes
Pharma
ESC says SGLT2s like Farxiga are first-line treatment in HF
The European Society of Cardiology issued new guidelines for heart failure, recommending SGLT2s such as AstraZeneca's Farxiga for first-line treatment
Kevin Dunleavy
Aug 28, 2021 1:35pm
Bayer's Kerendia racks up cardio benefits in outcomes trials
Aug 28, 2021 11:25am
Amarin touts Vascepa in preventing repeat heart problems
Aug 23, 2021 11:58am
Fujifilm, WuXi STA, Hanmi, BeiGene and more—Fierce Pharma Asia
Jul 2, 2021 9:28am
FDA weighs tighter restrictions for Pfizer's Xeljanz
Feb 5, 2021 10:55am
Amarin's Vascepa cuts CV events in patients with artery grafts
Nov 16, 2020 11:30am